This may suggest that in CML patients with enhanced PCNA expression, the levels of PAK2 and ERK3 are also elevated and these perturbed expression levels may be implicated in the development of CML. The gene discussed is PAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.